Challenges and advances in clinical applications of mesenchymal stromal cells

被引:0
作者
Tian Zhou
Zenan Yuan
Jianyu Weng
Duanqing Pei
Xin Du
Chang He
Peilong Lai
机构
[1] Guangdong Academy of Medical Sciences,Department of Hematology, Guangdong Provincial People’s Hospital
[2] Zhongshan Ophthalmic Center,State Key Laboratory of Ophthalmology
[3] Sun Yat-Sen University,Department of Hepatic Surgery and Liver Transplantation Center
[4] The Third Affiliated Hospital of Sun Yat-Sen University,Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health
[5] University of Chinese Academy of Sciences,undefined
[6] Chinese Academy of Sciences,undefined
来源
Journal of Hematology & Oncology | / 14卷
关键词
Mesenchymal stromal cells; Clinical applications; Heterogeneity; Artificial intelligence (AI); Extracellular vesicles; COVID-19;
D O I
暂无
中图分类号
学科分类号
摘要
Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been intensely investigated for clinical applications within the last decades. However, the majority of registered clinical trials applying MSC therapy for diverse human diseases have fallen short of expectations, despite the encouraging pre-clinical outcomes in varied animal disease models. This can be attributable to inconsistent criteria for MSCs identity across studies and their inherited heterogeneity. Nowadays, with the emergence of advanced biological techniques and substantial improvements in bio-engineered materials, strategies have been developed to overcome clinical challenges in MSC application. Here in this review, we will discuss the major challenges of MSC therapies in clinical application, the factors impacting the diversity of MSCs, the potential approaches that modify MSC products with the highest therapeutic potential, and finally the usage of MSCs for COVID-19 pandemic disease.
引用
收藏
相关论文
共 1082 条
[1]  
Pittenger MF(1999)Multilineage potential of adult human mesenchymal stem cells Science 284 143-147
[2]  
Mackay AM(2020)Tissue-specific mesenchymal stem cell-dependent osteogenesis in highly porous chitosan-based bone analogs Stem Cells Transl Med 37 469-479
[3]  
Beck SC(2005)Mesenchymal stem cells Ann Med 35 e00191-927
[4]  
Jaiswal RK(2015)Human mesenchymal stem cells—current trends and future prospective Biosci Rep 29 920-294
[5]  
Douglas R(2011)Concise review: Mesenchymal stem cell tumor-homing: detection methods in disease model systems Stem Cells 6 6884-344
[6]  
Mosca JD(2020)Shattering barriers toward clinically meaningful MSC therapies Sci Adv 17 285-621
[7]  
Midha S(2019)Subconjunctival injection of mesenchymal stromal cells protects the cornea in an experimental model of GVHD Ocul Surf 73 337-1423
[8]  
Jain KG(2016)Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials JAMA Neurol 9 46-821
[9]  
Bhaskar N(2016)The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation J Hematol Oncol 6 613-289
[10]  
Kaur A(2017)Cartilage regeneration in osteoarthritic patients by a composite of allogeneic umbilical cord blood-derived mesenchymal stem cells and hyaluronate hydrogel: results from a clinical trial for safety and proof-of-concept with 7 years of extended follow-up Stem Cells Transl Med 320 1421-260